It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In this study, we have designed an anticancer drug delivery framework by a one-pot technique using a zeolitic imidazolate framework (ZIF) as the carrier. The chitosan-coated Aminopterin (AMT) loaded with zeolitic imidazolate framework (ZIF-90) CS@AMT@ZIF-90 (CAZ-90) for breast cancer cells. The particle’s outer layer changed Chitosan (CS), a pH-sensitive biomaterial, to increase the composite CAZ-90’s reactivity to pH during drug release. CAZ-90 displayed target-selective and pH-responsive by releasing a significant ratio of AMT under an acidic milieu and a considerably reduced amount of AMT in a normal milieu. Additionally, CAZ-90 was found to have low toxicity to normal Human umbilical vein endothelial cells (HUVECs) cells while inhibiting breast cancer 4T1, MDA-MB-231, and MCF-7 cells in vitro. Further, cell death was investigated by two different staining methods (AO-EB and DAPI nuclear staining). RNase-PI staining by flow cytometry techniques investigated the cell cycle arrest in breast (4T1, MDA-MB-231, and MCF-7) cancer cells. CAZ-90 showed high AMT drug loading, cancer-targeted release, and excellent biocompatibility in the related tests, making it a promising option for an anticancer drug delivery system.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Thyroid and Breast Surgery, The First People’s Hospital of Wenling, Wenling, China